PGEN

Precigen, Inc. (PGEN) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Precigen, Inc. is a commercial-stage biopharmaceutical company. The reporting period marks a significant transition as the Company achieved profitability for the first time since its 2020 strategic transformation, driven by the commercial launch of Papzimeos (zopapogene imadenovec-drba), the first FDA-approved therapy for recurrent respiratory papillomatosis (RRP). The Company operates as a single segment and maintains a subsidiary, Exemplar Genetics, LLC, focused on miniature swine research models.

Key Financial Metrics

Note: Cash and Investments as of June 30, 2026, includes $16.3M cash and $21.9M short-term investments. Long-term debt principal is $100M with a carrying value of $93.9M.

Material Changes vs. Prior Period

• Revenue Surge: Total revenues increased by over 6,000% year-over-year for the six months ended June 30, 2026. This is primarily due to Papzimeos sales of $74.7M (YTD 2026) compared to zero in the prior year, following FDA approval in August 2025.
• Profitability Turnaround: The Company reported a net income of $20.1M for Q2 2026, reversing a net loss of $26.6M in Q2 2025. Operating income improved by $54.4M.
• Expense Shifts:
  • R&D Expenses: Decreased 41.2% YTD (from $22.0M to $12.9M) because manufacturing costs for Papzimeos are now capitalized as inventory rather than expensed as R&D.
  • SG&A Expenses: Increased 52.0% YTD (from $28.5M to $43.3M) due to commercialization costs, marketing, and personnel expansion for Papzimeos.
  • Other Income/Expense: Improved significantly due to the absence of a $28.0M non-cash charge related to warrant liability fair value adjustments recorded in 2025. However, interest expense increased by $5.9M YTD due to a new $100M term loan secured in September 2025.
• Balance Sheet: Accounts receivable surged to $71.9M (from $3.9M) due to 127-day payment terms for Papzimeos. Inventory increased to $20.2M to support commercial sales.

Guidance, Outlook, and Risks

• Commercial Outlook: Management expects gross margins to stabilize between the high 80% and low 90% range once pre-launch inventory is fully sold (expected Q3 2026). Current margins are higher due to the sale of pre-launch inventory which excludes certain period costs.
• Liquidity: Management believes existing liquid assets ($38.7M) and anticipated Papzimeos collections will fund operations for at least one year. The Company has a $100M term loan maturing in 2030 with a 6.5% margin over SOFR (floored at 3.75%).
• Pipeline:
  • Papzimeos: Granted 7-year orphan drug exclusivity in the U.S. through 2032. MAA submitted to EMA.
  • PRGN-2009: Phase 2 trials for HPV+ oropharyngeal cancer and cervical cancer ongoing.
  • UltraCAR-T: PRGN-3006 (AML) Phase 1b enrollment complete; seeking partnerships. PRGN-3005 and PRGN-3007 trials paused per strategic prioritization.
• Risks: Key risks include forecasted demand for Papzimeos, payer coverage/reimbursement, manufacturing scalability, and the need for additional capital if revenue growth does not meet projections. The Company remains subject to litigation risks, though none are currently deemed material.

Investor Verification Checklist

• Revenue Recognition: Verify the sustainability of Papzimeos sales velocity and the impact of the 127-day payment cycle on cash flow conversion.
• Gross Margin Trajectory: Monitor the transition from selling pre-launch inventory to standard commercial inventory to confirm the projected 80-90% gross margin stabilization.
• Debt Covenants: Review compliance with the $100M term loan covenants, specifically minimum net sales and liquidity requirements.
• Reimbursement Status: Confirm payer coverage and reimbursement rates for Papzimeos, which are critical for long-term commercial success.
• Inventory Valuation: Assess the $20.2M inventory balance for potential obsolescence or write-downs if sales targets are not met.